?Brinzolamide | USP/EP-Certified Bulk API for Glaucoma Therapy & Ophthalmic Formulations?

?? ?Product Overview?

Brinzolamide, a ?topical carbonic anhydrase inhibitor (CAI)?, is widely used in ?glaucoma treatment? and ?ocular hypertension management? to reduce intraocular pressure (IOP) by suppressing aqueous humor production?14. Its high selectivity and minimal systemic absorption make it ideal for sustained ophthalmic drug delivery?13.

?? ?Key Features?

• ?Regulatory Compliance?

  : Manufactured under 

  ?USP/EP standards?

   with ≥99% HPLC purity for pharmaceutical-grade applications?35.

• ?Enhanced Stability?

  : 24-month shelf life in sealed, light-protected packaging (2-8°C storage)?56.

• ?Mechanistic Precision?

  : Targets CA-II isoenzymes in ciliary processes, ensuring localized efficacy without compromising corneal clarity?14.

?? ?Applications?

• ?Ophthalmic Solutions?

  : Core API in 

  ?glaucoma eye drops?

   (e.g., Azopt? generics) and 

  ?combination therapies?

   with beta-blockers?34.

• ?Research Use?

  : Critical for 

  ?ocular pharmacology studies?

   and 

  ?novel CA inhibitor development?

  ?16.

?? ?Quality Assurance?

• ?Batch Documentation?

  : COA, MSDS, and ICH-compliant impurity profiles (total impurities <0.2%)?56.

• ?Packaging Options?

  : Available in 

  ?100g amber glass bottles?

   and 

  ?5kg vacuum-sealed HDPE containers?

  ?36.